Mediolanum International Funds Ltd Has $726,000 Stake in STERIS plc $STE

Mediolanum International Funds Ltd trimmed its stake in STERIS plc (NYSE:STE) by 92.0% during the 1st quarter, HoldingsChannel.com reports. The firm owned 3,309 shares of the medical equipment provider’s stock after selling 38,225 shares during the period. Mediolanum International Funds Ltd’s holdings in STERIS were worth $726,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bessemer Group Inc. raised its position in shares of STERIS by 8.8% during the first quarter. Bessemer Group Inc. now owns 1,048,636 shares of the medical equipment provider’s stock valued at $231,883,000 after buying an additional 85,188 shares during the last quarter. Illinois Municipal Retirement Fund grew its position in STERIS by 134.9% during the first quarter. Illinois Municipal Retirement Fund now owns 3,770 shares of the medical equipment provider’s stock worth $834,000 after buying an additional 2,165 shares in the last quarter. Checchi Capital Advisers LLC grew its position in STERIS by 14.0% during the first quarter. Checchi Capital Advisers LLC now owns 995 shares of the medical equipment provider’s stock worth $220,000 after buying an additional 122 shares in the last quarter. Principal Financial Group Inc. increased its stake in STERIS by 1.0% during the first quarter. Principal Financial Group Inc. now owns 890,562 shares of the medical equipment provider’s stock valued at $196,931,000 after acquiring an additional 9,226 shares during the period. Finally, Procyon Advisors LLC increased its stake in STERIS by 60.2% during the first quarter. Procyon Advisors LLC now owns 1,312 shares of the medical equipment provider’s stock valued at $290,000 after acquiring an additional 493 shares during the period. Institutional investors own 94.69% of the company’s stock.

STERIS Stock Performance

NYSE STE opened at $211.49 on Wednesday. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The stock has a market cap of $20.61 billion, a P/E ratio of 26.67 and a beta of 0.92. The company’s 50-day simple moving average is $211.75 and its 200 day simple moving average is $228.27.

STERIS (NYSE:STE) last announced its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The business had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, research analysts forecast that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 26th. Investors of record on Monday, June 8th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date was Monday, June 8th. STERIS’s dividend payout ratio (DPR) is 31.78%.

Insider Buying and Selling

In other STERIS news, CEO Daniel A. Carestio sold 3,054 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $214.64, for a total value of $655,510.56. Following the sale, the chief executive officer directly owned 65,021 shares in the company, valued at $13,956,107.44. This represents a 4.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the transaction, the director owned 38,964 shares of the company’s stock, valued at $8,163,347.64. This represents a 3.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 7,328 shares of company stock worth $1,554,051 in the last 90 days. 1.12% of the stock is owned by company insiders.

Analyst Ratings Changes

STE has been the subject of a number of research reports. Piper Sandler reiterated an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a research report on Thursday, May 21st. Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 27th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. Finally, KeyCorp reduced their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research report on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.